| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.27 | 8e-10 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | 0.27 | 1e-09 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.18 | 9e-06 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.18 | 1e-05 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-05 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-05 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | -0.17 | 5e-05 |
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | -0.17 | 6e-05 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.15 | 7e-05 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0001 |